HiberCell
Präsenz
HiberCell hat 7 Tochterunternehmen, einschließlich Genuity Science, WuXi Advanced Therapies und WuXi AppTec.
Führungskräfte
Siehe das Organigramm mit seine 95 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei HiberCell
- Jonathan Lanfear, President and Chief Executive Officer
- Colin Goddard, Director
- Steven Gillis, Chairman of the Board
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von HiberCell nachzuverfolgen.
Biotechnologie
HiberCell hat 2.292 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Adaptive Phage Therapeutics (USA).
Popular M&A news in Biotechnologie
- Lycia Therapeutics hat gerade eine Spendenaktion von 107 Millionen Dollar angekündigt. (veröffentlicht am 15, Mai 2024).
- Attovia Therapeutics hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 14, Mai 2024).
- Bruker has announced the acquisition of NanoString Technologies (veröffentlicht am 13, Mai 2024).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach HiberCell
- HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
- HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
- HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance Setting - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023 - HiberCell
- HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML) - HiberCell
- HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - HiberCell
- HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting - HiberCell
- HiberCell and the University of Pennsylvania Present Preclinical Anti-Metastatic Monotherapy Activity Data in Mice for Odetiglucan in Pancreatic Cancer at AACR Annual Meeting 2022 - HiberCell
- View more press releases Close
Social media about HiberCell
- HiberCell auf Wikipedia, Google News & Yahoo Finance
- HiberCell auf LinkedIn, Twitter & YouTube
In Kontakt kommen
Jetzt seine Führungskräfte, darunter auch Jonathan Lanfear, per E-Mail kontaktieren. 
HiberCell unter +1 212... anrufen
